Drug resistance of HIV-1 as a result of using nevirapine for chemoprophylaxis of vertical viral transmission from HIV-infected mother to infant


Cite item

Full Text

Abstract

The review presents data on the use of a single prophylactic dose of nevirapine at labor given to a mother at the onset of labor in HIV-infected women and neonatal infants within 72 hours after birth in the absence of chemoprophylaxis with antiviral agents during pregnancy. The administration of nevirapine is shown to result in the occurrence of resistance mutations, most of which can be identified only if superfine methods are applied. Whether nevirapine may be used for chemoprophylaxis of the vertical transmission of the virus in Russia is discussed.

References

  1. Бобков А. Ф., Казеннова Е. В., Бобкова М. Р. и др. Молекулярно-эпидемиологическая характеристика ВИЧ-1 на территории России // Вестн. РАМН. - 2002. - Т. 8. - С. 40-42.
  2. Инструкция по профилактике передачи ВИЧ-инфекции от матери ребенку во время беременности, родов и в период новорожденности. Приказ № 606 МЗ РФ от 19.12.2003. - М., 2003.
  3. Суханова А. Л., Рудинский Н. И., Богословская Е. В. и др. Полиморфизм области генома, кодирующий протеазу и обратную транскриптазу, вариантов ВИЧ-1 подтипа А, распространенных на территории СНГ // Молекул. биол. - 2005. - Т. 39. - С. 1063-1071.
  4. Barre-Sinoussi F., Chermann J. C., Rey F. et al. Isolation of T-lymphotropic retrovirus from a patient at a risk for acquired immune deficiency syndrome (AIDS) // Science. - 1983. - Vol. 220. - P. 868-871.
  5. Bobkov A., Kazennova E., Selimova L. et al. A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: Identification of subtype A, subtype B, and novel gagA/envB recombinants // AIDS Res. Hum. Retrovirus. - 1998. - Vol. 14. - P. 669-676.
  6. Chaix M. L., Dabis F., Fkouevi D. et al. Addition of 3 days ZDV+3TC Hjstpartum to short course of ZDV+3TC and single-dose NVP provide slow rate of NVP resistance mutations and high efficacy in preventing peri-partum HIV-1 transmission: ANRS DITRAME Plus, Abidjan, Cote d'Ivoire // 12-th Retrovirus Conference. - Boston, 2005. - Abstr. 72LB.
  7. Chung M. H., Kiarie J. N., Richardson B. A. et al. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine // AIDS. - 2005. - Vol. 19. - P. 1415-1422.
  8. Collins J. A., Thompson M. G., Painysil E. et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants // J. Virol. - 2004. - Vol. 78. - P. 603-611.
  9. Connor E. M., Sperling R. S., Gelber R. et al. The Pediatric AIDS Clinical Trials Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment // N. Engl. J. Med. - 1994. - Vol. 331. - P. 1173-1180.
  10. Coovadia H., Fowler M. G., Lokman S., Mcintyre J. Revisiting the role of single-dose nevirapine for preventing perinatal HIV transmission // AIDS Clin. Care. - 2005. - Vol. 17. - P. 61-64.
  11. Coovadia H. Antiretroviral agents - how best to protect infants from HIV and save their mothers from AIDS // N. Engl. J. Med. - 2004. - Vol. 351. - P. 289-292.
  12. Cunningham C. K., Chaix M. L., Rekacewicz C. et al. Development of resistrance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trial Group protocol 316 // J. Infect. Dis. - 2002. - Vol. 186. - P. 181-188.
  13. Dabis F., Bequet L., Ekouevi D. K. et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission // AIDS. - 2005. - Vol. 19. - P. 309-318.
  14. Eshleman S., Mracna M., Guay L. et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) // AIDS. - 2001. - Vol. 15. - P. 1951-1957.
  15. Eshleman S. H., Guay L. A., Mwatha A. et al. Characterisation of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (NIVNET 012) // J. Acquir. Immune Defic. Syndr. - 2004. - Vol. 35. - P. 126-130.
  16. Eshleman S., Hoover D. R., Chen S. et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtype A and D, after the administration of single-dose NVP // J. Infect. Dis. - 2005. - Vol. 192. - P. 30-36.
  17. Eshleman S. H., Guay L. A., Mwatha A. et al. Comparison of mother-to-child transmission rates in Uganda women with A versus D HIV-1 who received single-dose nevirapine prophylaxis - HIV Network for prevention Trial 012 // J. Acquir. Immune Defic. Syndr. - 2005. - Vol. 39. - P. 593-597.
  18. Eshleman S., Guay L., Wang J. t al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose Nevirapine // AIDS. - 2005. - Vol. 40. - P. 24-29.
  19. Eshleman S., Hoover D. R., Hudelson S. E. et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1 // J. Infect. Dis. - 2006. - Vol. 193. - P. 479-481.
  20. Flint S. J., Enquist L. W., Krug R. M. Principles of Virology. Molecular Biology, Pathogenesis, and Control. - Washington, 2000. - P. 207-210.
  21. Floridia M., Buccardini R., Ricciardulli D. et al. A randomized double-blind trial on the use of a triple combination including nevirapine, a non-nucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advance disease // J. Acquir. Immune Defic. Syndr. - 1999. - Vol. 20. - P. 11-19.
  22. Flys T., Nissley D. V., Claasen C. W. et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP:HIVNET 012 // J. Infect. Dis. - 2005. - Vol. 192. - P. 24-29.
  23. Frederick T., Jackson-Alvarez J., Shin Y. S., Mascola L. Decreasing rates of perinatal HIV trasmission in Los Angeles County (LAC): Trends from 1990-2000// XIV International AIDS Conference. - Barcelona, 2002. - Abstr. TulieC4764.
  24. Gao F., Chen Y., Levy D. N. et al. Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious // J. Virol. - 2004. - Vol. 78. - P. 2426-2433.
  25. Hirsch M. S., Brun-Vezinet F., Clotet B. et al. Antiretroviral drug-resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel // Clin. Infect. Dis. - 2003. - Vol. 37. - P. 113-128.
  26. Jackson J. B., Musoke P., Fleming N. et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 month follow-up of the HIVNET 012 randomised trial // Lancet. - 2003. - Vol. 362. - P. 859-868.
  27. Jackson J. B., Parsons T., Musoke P. et al. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission // AIDS. - 2005. - Vol. 20. - P. 217-222.
  28. Johnson J. A., Li J.-F., Morris I. et al. Emergence of drug resistant HIV-1 after intrapartum administration of single-dose nevirapine in substantially underestimated // J. Infect. Dis. - 2005. - Vol. 192. - P. 16-23.
  29. Kahn J. G., Marcelle E. Control trails of short-course antiretroviral regimens to reduce mother-to-child HIV transmission are essential to establish standard of care in Africa // XII World AIDS Conference. - Geneva, 1998. - Abstr. Li.813.
  30. Kantor R., Lee E., Johnston E. et al. Rapid Flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine // Antivir. Ther. - 2003. - Vol. 8. - P. S85.
  31. Lallemant M., Jourdain G., Le Coeur S. et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand // N. Engl. J. Med. - 2004. - Vol. 351. - P. 217-228.
  32. Little S. J., Dawson K., Hellmann N. S. et al. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring therapy // Antivir. Ther. - 2003. - Vol. 8. - P. S129.
  33. Martinson N., Pumla L., Morris L. et al. Effectiveness of single-dose nevirapine in a second pregnancy // 12-th Retrovirus Conference. - Boston, 2005. - Abstr. 103.
  34. Merluzzi V., Hargrave K., Labadia M. et al. Inhibitor of HIV-1 replication by nonnucleoside reverse transcriptase inhibitors // Science. - 1990. - Vol. 250. - P. 1411-1423.
  35. Milinkovic A., Martinez E. Nevirapine in the treatment of HIV // Expert. Rev. Antiinfect. Ther. - 2004. - Vol. 2. - P. 90-95.
  36. Mirochnick M., Fenton T., Gagnier P. et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women an their neonates // J. Infect. Dis. - 1998. - Vol. 178. - P. 368-374.
  37. Morris L., Martinson N., Pillay C. et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine // XV International AIDS Conference. - Bangkok, 2004. - Abstr. ThOrB1353.
  38. Petropoulos C. J., Chaooey C., Parkin N. T. High-level resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the asense of known resistance mutations // 43-rd ICAAC. - Chicago, 2003. - Abstr. H-451.
  39. Quinones-Mateu M. E., Arts E. J. Fitness: implications for drug resistance, disease progression, and global epidemic evolution // HIV Sequence Compendium 2001 /Eds C. Kuiken et al. - Los Alamos, 2001. - LA-UR 02-2877.
  40. Rodgers D., Gamblin S., Haris B. et al. The structure of uniligand reverse trascriptase from the HIV type 1 // Proc. Natl. Acad. Sci. USA. - 1995. - Vol. 92. - P. 1222-1230.
  41. Sint T., Dabis F., Kamenga C. et al. Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus? // Bull. WHO. - 2005. - Vol. 83. - P. 224-228.
  42. Vocks-Hauck M. Pregnancy and HIV. Therapy for mothers and prevention for neonates // HIV Medicine. - 2005. - P. 333-334; www.HIV Medicine: com.
  43. Wei X., Ghosh S. K., Taylor M. E. et al. Viral dynamics in human immunodeficiency virus type 1 infection // Nature. - 1995. - Vol. 373. - P. 117-122.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Kazennova E.V., Kazennova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies